key: cord-1041710-npc9qdex
authors: Gupta, Tania; Gupta, Shishir K
title: Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses
date: 2020-06-18
journal: Int Immunopharmacol
DOI: 10.1016/j.intimp.2020.106717
sha: a86d4e3cbd75226a37abee98ce89785e48959bba
doc_id: 1041710
cord_uid: npc9qdex

The extensive efforts around the globe are being made to develop a suitable vaccine against COVID-19 (Coronavirus Disease-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). An effective vaccine should be able to induce high titers of neutralizing antibodies to prevent the virus from attaching to the host cell receptors. However, to elicit the protective levels of antibodies, a vaccine may require multiple doses or assistance from other immunostimulatory molecules. Further, the vaccine should be able to induce protective levels of antibodies rapidly with the least amount of antigen used. This not only decreases the cost of a vaccine and make it affordable, but also reduces the quantity of the antigen used. As the pandemic has hit most countries across the globe, there will be an overwhelming demand for the vaccine in a quick time. Incorporating a suitable adjuvant in a SARS-CoV-2 vaccine may address these requirements. This review paper will discuss the experimental results of the adjuvanted vaccine studies with similar coronaviruses (CoVs) which might be useful to select an appropriate adjuvant for a vaccine against rapidly emerging SARS-CoV-2. We also discuss the current progress in the development of adjuvanted vaccines against the disease.

The SARS-CoV-2, a member of family Coronaviridae and the causative agent of COVID-19 disease, has spread rapidly around the globe since the first outbreak in Wuhan, China in December 2019. The World Health Organization (WHO) declared the outbreak as the sixth public health emergency of international concern on 30 th January 2020 [1] [2] [3] [4] . Despite the tremendous efforts to contain the virus, its spread is ongoing. Though the majority of cases resolve spontaneously, some develop various fatal complications, including organ failure, septic shock, pulmonary edema, severe pneumonia, and Acute Respiratory Distress Syndrome (ARDS) [5] [6] [7] . Before the current pandemic, highly pathogenic CoVs have hit the world as severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East Respiratory Syndrome (MERS) coronavirus in 2012. The SARS-CoV-2 has been identified as a β-coronavirus, and like SARS-CoV, it binds to angiotensin-converting enzyme 2 (ACE2) receptors [8, 9] . Recent data on genome sequencing of SARS-CoV-2 revealed that it shares approximately 79.6% similarity with SARS-CoV at the nucleotide level [9] , which varies between the different genes. SARS-CoV-2 contains a linear single-stranded positive-sense RNA as genetic material that encodes for the spike (S), envelop (E), membrane (M), and nucleocapsid (N) proteins [10] . The spike protein that binds to host cell receptors shares about 72% nucleotide similarity between these two [8, [11] [12] [13] . The S protein consists of two subunits S1 and S2, S1 interacts with the surface receptor and S2 helps in the fusion of viral and cellular membranes, and subsequent entry of the virus into the host cells. Different coronaviruses, depending upon the viral species, use different receptor binding domains (RBD) present on the S1 subunit to interact with host cell receptors [8, 9] . While RBD of MERS-CoV recognizes non-acetylated sialoside attachment receptors (human dipeptidyl peptidase 4) [14, 15] , SARS-CoV interacts with ACE2 receptors [16] . However, SARS-CoV-2, as compared to SARS-CoV, contains different amino acids (five amino acids out of six are mutated) composition in its RBD that are crucial for receptor binding (ACE2) with high affinity [17] , and has a functional polybasic furin site at S1-S2 boundary that may have a role in defining the viral infectivity and host range [18, 19] . The furin cleavage site is not reported in SARS-CoV, and its fusion to membrane involves either direct receptor-mediated fusion or receptor-mediated endocytosis [20] . The high-affinity binding of SARS-CoV-2 with ACE2 receptor along with the presence of furin and TMPRSS2 (at S2') cleavage sites explain its rapid spread and strong ability for human to human transmission [21] .

Currently, there is no specific anti-viral medicine or vaccine available for the disease; however, many studies and clinical trials are being undertaken to assess the efficacy and safety of various drugs and vaccine candidates [22] . As SARS-CoV-2 share significant similarities with SARS and MERS coronaviruses and use similar spike protein for receptor binding, the key information from the past vaccine studies with such similar viruses, may help accelerate the development of an effective therapy/vaccine against COVID-19. [26, 27] . Further, as with other RNA viruses, these CoVs go through frequent recombination; therefore, a live attenuated vaccine carries the inherent risk of reversal to a virulent form and may pose a severe threat to human lives. Ideally, a vaccine against a highly pathogenic virus, including CoVs should be able to generate a protective antibody response to the minimum antigen dose in a quick time with no adverse reactions. The COVID-19 is spreading globally and infecting a large number of people due to the lack of any prophylactic measure. The demand for the vaccine, once available, will be overwhelming, and therefore; highly desirable for a potential vaccine to be able to induce immunity in a short time with the minimum quantity of the antigen required.

This will make it affordable and help meet the high global demands [28, 29] . Most of the above issues may be resolved by incorporating a suitable adjuvant in vaccine preparations, which will not only help in eliciting a robust immune response but also possibly reduce the antigen quantity and the need for multiple doses of vaccine. Thus, the selection of an effective adjuvant becomes crucial for the development of an adjuvanted vaccine against COVID-19. The past vaccine studies on similar CoVs with various adjuvant combinations may provide key information and help in picking adjuvants which possess a good safety profile and efficacy. Therefore, in this review, we discuss the past adjuvanted vaccine studies and their outcomes, with similar CoVs which might be useful in developing an adjuvanted vaccine against COVID-19. Further, we briefly discuss the current progress in the development of adjuvanted vaccines against COVID-19.

Aluminum hydroxide (alum) is the most commonly used agent as an adjuvant. The mechanism of its adjuvant action is complex and, so far, multiple hypotheses have been put forward to explain its mode of action [153] . It has been shown to act by depot formation at the site of injection allowing for a slow release of antigen. This prolongs the interaction time between antigen and antigen-presenting cells (APCs). Further, it converts soluble antigens into particulate forms which are readily phagocytosed [30] . At the cellular level, aluminum hydroxide directly stimulates monocytes to produce pro-inflammatory cytokines activating T cells. Activated Th2 cells release IL-4, which in turn can induce an increase in the expression of MHC class II molecules on monocytes [31] . Alum has been approved as an adjuvant in multiple licensed vaccines for human use in the majority of the countries worldwide (Table. 1 (Table. 2 (Table. 3) [52, 53]

MF59 is an oil-in-water type immunogenic adjuvant which consists of squalene and two surfactants, Tween 80 and Span 85. The MF59 is a safe, well-tolerated, and potent adjuvant that has been used in pandemic (Focetria® and Celtura®) and seasonal influenza (Fluad®) vaccines in many countries (Table. 1) [54, 55] . The inclusion of the MF59 adjuvant in the influenza vaccine has been reported to induce higher levels of antigen-specific antibody levels, higher HAI titers (hemagglutination inhibiting), and better protection [56] [57] [58] . Though it favors Th2-type response like alum, MF59 activates more CD4 T cells and produces higher antibody tiers against the HA (hemagglutinin) of the influenza virus [59] . The MF59 has been tested as an adjuvant with many other vaccines against bacteria and viruses, including SARS-CoV.

Immunization with inactivated SARS-CoV vaccine adjuvanted with MF59 protected mice from challenge with the virus. The vaccine was able to elicit neutralizing antibodies after only 2 doses [60] . Subunit vaccines based on S1 protein and RBD epitopes of MERS-CoV when co-administered with MF59, significantly augmented their immunogenicity resulting in strong induction of IgG and neutralizing antibody response. The preparations protected the mice from lethal virus challenge [61] [62] [63] . Many MERS-CoV RBD candidate vaccines adjuvanted with MF59 were developed and tested in mice. These vaccines elicited neutralizing antibodies and protected the hDPP4 transduced mice from the lethal challenge (Table. 3) [63, 64] .

Montanide is a water-in-oil (w/o) emulsion that contains mineral oil and surfactant from mannide monooleate family. It possesses immunostimulatory activity and works by the depot formation at the site of injection resulting in a slower release of antigens, local inflammation, and recruitment of antigen-presenting cells (APCs). It enhances antibody titer as well as cytotoxic T-lymphocyte (CTL) activity against the antigen it is formulated with [65, 66] . It is well tolerated in humans as compared to FIA (Freund's Incomplete Adjuvant) and has been tested in vaccines against AIDS (Acquired Immunodeficiency Syndrome), malaria, cancer, and influenza with varying degree of success [67] [68] [69] [70] . The combination of Montanide ISA-51 and CpG ODN (oligodeoxynucleotide) has been used widely in many vaccines as the combination exerts a synergistic effect in boosting the Th1 immune response. Montanide ISA-51 and CpG were used to emulsify the recombinant N protein of SARS-CoV. The formulation elicited strong Th1 immune responses in mice and macaques [71] . The synthetic peptides of the spike protein of SARS-CoV formulated with an adjuvant Montanide ISA-51/CpG combination, elicited strong antibody titer in immunized animals that were capable of inhibiting SARS-CoV pseudovirus entry into HepG2 cells [72] . A DNA vaccine encoding SARS-CoV N protein elicited a potent N protein-specific immune response when co-administered with Montanide ISA-51/CpG adjuvants [73] . The recombinant RBD of MERS-CoV when adjuvanted with Montanide ISA-51, induced high titers of serum antibodies that could neutralize the virus in cell culture [74] . The above pieces of evidence from the previous studies indicate that Montanide ISA-51 may increase the immunogenicity of the vaccines based on recombinant spike protein or synthetic peptides corresponding to RBD of S protein. Further, it may be used along with CpG ODN to induce an overall Th1 biased immune response as a predominantly Th2 immune response seems to cause ADE on the viral challenge following immunization.

These are oil-in-water adjuvant systems developed by GlaxoSmithKline (GSK). The AS01

(adjuvant system 01) is a liposome-based adjuvant that is consist of monophosphoryl lipid A (MPL) and a saponin molecule (QS-21), whereas AS03 (adjuvant system 03) is an α-tocopherol and squalene-based adjuvant that has been used in GSK's A/H1N1 pandemic flu vaccine Pandemrix®. The MPL is extracted from Salmonella minnesota and QS-21 is purified from the bark of the South American tree Quillaja saponaria Molina. The MPL signals through Tolllike receptor-4 (TLR4), which results in the activation of APCs and the production of cytokines and interferons (IFNs). Q-21 is reported to induce antigen-specific antibody response as well as cell-mediated immunity [75, 76] . When co-administered with recombinant SARS-CoV S protein, Q-21 induced high titers of antigen-specific serum antibodies and protected from viral infection [77]. The AS01 system has been used in recently developed RTS,S/AS01 malaria vaccine as well as tested in Herpes zoster subunit vaccine, polyprotein HIV-1 vaccine and tuberculosis (Mtb72F/AS02 candidate) vaccine [78-81]. Further, these adjuvants have also been used with inactivated SARS-CoV vaccine preparation in mice and hamsters. The AS01 Badjuvanted vaccine was slightly more immunogenic than the AS03 A -adjuvanted vaccine. The vaccine in animals immunized with adjuvant provided better protection than the nonadjuvanted vaccine. Importantly, the study did not observe enhance disease (ADE) in the lungs or liver of hamsters following SARS-CoV challenge [82].

Delta inulin (DI) is one of the many isoforms of inulin polysaccharide, which is stable at a higher temperature and has better immune potency. It activates the complement system and, when co-administered with antigen, helps mount a robust antigen-specific adaptive immune response consisting of both antibody and cell-mediated immunity (a Th0 adjuvant property)

[83-85]. A balanced enhancement of both Th1 and Th2 responses was observed when DI (Advax™) adjuvant was co-administered with an inactivated JEV (Japanese Encephalitis Virus) and influenza vaccines, which conferred the protection against the viral challenges [83, 86]. Similarly, when recombinant spike protein or inactivated SARS-CoV vaccine was coadministered with delta inulin plus CpG oligonucleotide as adjuvants, the combination significantly enhanced serum neutralizing antibody titers without causing lung immunopathology, which was not the case when alum was used instead of delta inulin [45].

TLRs are pattern recognition receptors (PRRs) that identify pathogen-associated molecular patterns (PAMPs). These are present on cell surfaces as well as in endosomal compartments.

Interaction with the appropriate ligand triggers the release of proinflammatory cytokines and type -1 IFNs (Interferons), which activates the cells of the innate and adaptive immune system 

Many helminth-derived molecules have been shown to have potent immunostimulatory effects, including ASP-1. The ASP-1 is present in helminth Onchocerca volvulus. A recombinant ASP-1 (rOv-ASP-1) is reported to induce a mix of Th1 and Th2 responses when included with vaccine antigen; however, depending on the antigen, it could also activate a predominantly Th1 type of immune response [100, 101] . Therefore, it can be beneficial in a condition where bits of help from both the arms of the immune response is needed to clear the infection. Further, the immune response induced against the ASP-1 protein adjuvant did not affect its adjuvant activity on subsequent boost [102] . ASP-1 has been shown to improve IgG1 and IgG2a antibody levels against commercially available vaccines such as influenza and rabies, and the adjuvant effect observed was higher than either traditional adjuvant alum, or MPL plus trehalose dicorynomycolate (TDM) [100, 103, 104] . A recombinant ASP-1 protein when included with recombinant SARS-CoV spike protein antigen or an RBD containing vaccine, the combinations induced a mixed immune response with Th1 dominance [100] . Similar findings were observed when rOv-ASP-1 was used as an adjuvant with either S protein of SARS-CoV or HIV-1gp120 [105] . Further, immunization with RBD of SARS-CoV plus rOv-ASP-1 in NHPs resulted in a high titer of neutralizing anti-RBD antibodies with only low levels of anti-rOv-ASP-1 antibodies [102] .

A complex of Proteosomes with LPS derived from Shigella flexneri is named as Protollin, whereas Proteosomes itself contain hydrophobic outer membrane proteins derived from Neisseria meningitides. Protollin exerts its immunostimulatory effect via TLR2 and TLR4 signaling resulting in the production of cytokines, IFNs, and the activation of APCs. Intranasal administration of Protollin with influenza antigen (split or recombinant HA) induced both serum IgG and mucosal secretory IgA that protected the mice from lethal virus challenge [106, 107] . Further, its application was shown to be effective in reducing allergic asthma in a mouse model [108] , protective against the development of pneumonia in a murine model of Shigella infection [109] and safe and well-tolerated in healthy adults [110] . Protollin was an effective, safe, and immunogenic and induced protective antibody response consisting of both serum IgG and mucosal IgA in humans when administered intranasally with trivalent influenza vaccine [111] . Protollin when administered intranasally with recombinant SARS-CoV S protein, induced significant levels of antigen-specific serum IgG and mucosal IgA antibodies as compared alum plus recombinant S protein administered via intramuscular route, and protected the mice from the live viral challenge [112] . Therefore, as evidence reflects, Protollin adjuvant appears to be safe and well-tolerated in human, more importantly, its ability to induce both serum and mucosal immunity might prove to be beneficial and should be explored further in SARS-CoV-2 vaccine development.

Many investigations have revealed an over activation of the immune system when an animal is challenged with the live virus following immunization. It causes immunopathological changes because of the excessive release of pro-inflammatory cytokines (cytokine storm) such as IL-2, IL-7, IL-8, IL-9, IL-10, IL-17, IL-1β, G-CSF, GM-CSF, and TNFα. [154] [155] [156] ]. ADE or immune enhancement occurs when a virus gains access into the immune cells while adhered to the antibodies, leading to an increase in infectivity and virulence of the virus. Once inside the cells, which aren't the usual target, the virus multiplies and releases its progenies infecting more cells [157] . Many viruses such as dengue, yellow fever, HIV, and CoVs have been reported to induce ADE [158] . Most pieces of evidence suggest viruses exploit the Fc receptor (FcR) on the immune cells to gain entry while being attached to the antibody-binding site of the antibodies. The Fc region of the antibody has a sequence that binds to complement system or immune cells expressing FcR receptors [159, 160] . The presence of high levels of nonneutralizing antibodies appears to be the primary reason that triggers ADE [43] . Other factors that contribute include low-affinity or sub-optimal levels of neutralizing antibodies and isotype of antibodies induced [42, 43,] . The presence of circulating antibodies against related epitopes from different strains or related viruses may also contribute to the enhancement of disease [161] . Though data is conflicting, it has been observed in many inactivated virus vaccine 

Recent data available on vaccine studies with SARS-CoV-2 in NHPs appears promising. An inactivated vaccine (PiCoVacc) adjuvanted with alum, elicited spike, and RBD proteinspecific neutralizing antibodies and protected the macaques on the viral challenge.

Importantly, the study did not observe ADE in immunized animals (Table. 4 ) [113] . The recombinant S1 protein of the virus fused with Fc and adjuvanted with saponin microemulsion, when administered to macaques, induced a strong anti-S1 neutralizing antibodies [114] . The Oxford University's vaccine candidate, ChAdOx1 nCoV-19 encoding the S protein of SARS-CoV-2, protected rhesus monkeys from developing pneumonia. The vaccine significantly reduced the viral loads in bronchoalveolar lavage fluid and respiratory tract tissue without causing disease enhancement in vaccinated monkeys [162] . Further, a recently concluded Phase I clinical trial with Ad5-nCoV (adenovirus Type 5 vector) expressing S protein vaccine reported promising findings. The vaccine has been found to be safe, well-tolerated and induced both humoral and cellular immunity [165] . Encouraging results have also been received from a recently concluded Phase I clinical trial for the MERS-CoV vaccine [ Table. GlaxoSmithKline has also teamed up with many firms such as Xiamen Innovax Biotech and Sanofi, to make its adjuvant technology available to the collaborators for their vaccine candidates [117] . Both Sanofi and Xiamen Innovax Biotech are using GSK's AS03 adjuvant (squalene-based) in their recombinant protein vaccine candidates. Similarly, CSL (Commonwealth Serum Laboratories, Australia) and Seqirus, Germany have tied up to use the MF59 adjuvant, which uses novel molecular-clam technology, in their COVID-19 vaccine candidate [118] . Novavax, (USA), on the other hand, is using its proprietary Matrix-M™ adjuvant for their vaccine candidate (NVX-CoV2373), consisting of nanoparticles carrying SARS-CoV-2 spike protein antigens [119] . Another Biopharma company, Soligenix, Inc., has collaborated with BTG Speciality Pharmaceutics. Soligenix will use a novel vaccine adjuvant (CoVaccine HT) from BTG, with its COVID-19 vaccine candidate [120]. CoVaccine HT is an oil-in-water emulsion consisting of sucrose fatty acid sulfate easter (SFASE) and squalene, which has been reported to induce both humoral as well as cell-mediated immunity [121, 122] . iBio has signed up an agreement with Infectious Disease Research Institute (IDRI, Seattle, US) in an effort to utilize their novel adjuvants such as GLA (Glucopyranosyl Lipid Adjuvant), a synthetic analogue of the MPL, for its SARS-CoV-2 VLP vaccine development [123, 124] .

The experience and knowledge generated from the past vaccine studies with different adjuvants The adjuvanted vaccine in mice induced neutralizing antibodies; however, also pr though it did not affect its adjuvanticity The vaccine also produced significant ne but did not produce much antibodies aga 17 rOv-ASP-1 SARS-CoV S peptide vaccine Mice Demonstrated that rOv-ASP-1 was a bet MPL + TDM. It enhanced production Th The adjuvanted vaccine produced high a peptide 18 Protollin SARS-CoV spike protein Mice The adjuvanted vaccine elicited high lev serum. The antibodies were neutralizing antigen-specific IgA levels. The vaccine challenge. 

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

A novel coronavirus outbreak of global health concern

A new coronavirus associated with human respiratory disease in China

World Health Organization, 2020. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Origin and evolution of pathogenic coronaviruses

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging microbes & infections

Coronaviruses: an overview of their replication and pathogenesis

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26

Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors

Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2

Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

MF59: a safe and potent adjuvant for human use

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert review of vaccines

MF59 adjuvant: the best insurance against influenza strain diversity

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine

Immunology and efficacy of MF59-adjuvanted vaccines

Effects of MF59 Adjuvant on Induction of Isotype-Switched IgG Antibodies and Protection after Immunization with T-Dependent Influenza Virus Vaccine in the Absence of CD4+ T Cells

SARS vaccine protective in mice

Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus

Chaperna-mediated assembly of ferritin-based Middle East respiratory syndromecoronavirus nanoparticles

Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection

A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection

Safety and tolerability evaluation of the use of Montanide ISA™ 51 as vaccine adjuvant: a systematic review

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines

CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine

Immunization with cocktail of HIVderived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity

Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission

Safety and immunogenicity of multimeric-001-a novel universal influenza vaccine

Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates

Identification of synthetic vaccine candidates against SARS CoV infection

A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses

Identification of receptor-binding domain in S protein of the novel human coronavirus MERS-CoV as an essential target for vaccine development

Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert review of vaccines

Immunogenicity of a receptorbinding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine

The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection

Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells

Ov-ASP-1, the Onchocerca volvulus homologue of the activation associated secreted protein family is immunostimulatory and can induce protective anti-larval immunity

The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates

Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines

An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses

rOv-ASP-1, a recombinant secreted protein of the helminth Onchocerca volvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens

Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge

Protollin™: a novel adjuvant for intranasal vaccines

ICOS-expressing CD4 T cells induced via TLR4 in the nasal mucosa are capable of inhibiting experimental allergic asthma

Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection

Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults

An intranasal proteosome-adjuvanted trivalent influenza vaccine is safe, immunogenic & efficacious in the human viral influenza challenge model. Serum IgG & mucosal IgA are important correlates of protection against illness associated with infection

Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice

Development of an inactivated vaccine candidate for SARS-CoV-2

Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates

The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement

Coronavirus-Vaccine-Candidate-Accelerates-Initiation-of-First-in-Human-Trial-to-Mid-May

CoVaccine HT™ adjuvant is superior to Freund's adjuvants in eliciting antibodies against the endogenous alarmin HMGB1

A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant

Aluminum vaccine adjuvants: are they safe?

Safety of MF59™ adjuvant

Comparative safety of vaccine adjuvants: a summary of current evidence and future needs

Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant

Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study

Poly-ICLC, a TLR3 agonist, induces transient Innate Immune Responses in Patients with Treated HIV-Infection: A Randomised Double-blinded Placebo Controlled Trial

Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients

Recent clinical trends in Toll-like receptor targeting therapeutics

Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults

CpG Oligodeoxynucleotides as adjuvants for clinical use

Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, doubleblind phase IIa studies

Enhanced humoral response to influenza vaccine in aged mice with a novel adjuvant

Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice

A novel intranasal Protollin™-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice

Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine

Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with

Montanide ISA 51 in rhesus macaques

Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT™ protects against blood-stage challenge in rhesus macaques

Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial

Matrix M TM adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4+ T cell responses in man

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, doseescalation trial

Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, nonrandomised, uncontrolled

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine

Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus

Recombinant receptor-binding domains of multiple Middle East respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants

MERS-CoV spike nanoparticles protect mice from MERS-CoV infection

The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm

Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

COVID-19: immunopathology and its implications for therapy

Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications

Antibody-dependent enhancement of virus infection and disease

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

Molecular mechanism for antibody-dependent enhancement of coronavirus entry

Is COVID-19 receiving ADE from other coronaviruses? Microbes and infection

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques

Immunogenicity of a DNA vaccine candidate for COVID-19

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Clover Biopharmaceutics, China & Dynavax Technologies Corp

Recombinant protein vaccine AS03 Xiamen Innovax Biotech & GlaxoSmithKline

Recombinant protein vaccine AS03 Sanofi & GlaxoSmithKline

Recombinant protein vaccine MF59 adjuvant Commonwealth Serum Laboratories

SARS-CoV-2 spike protein nanoparticles Matrix-M™ Novavax

SARS-CoV-2 VLP vaccine Yes iBIO & Infectious Disease Research Institute (IDRI

Inactivated virus vaccine CpG 1018

Inactivated virus vaccine CpG 1018

SARS-CoV-2 protein subunit (RBD) Yes Biological E Ltd

Recombinant spike protein Advax™ (delta inulin) Vaxine Pty Ltd

No.

Vaccine candidate Animal model Results